Amikacin Sulfate Injection USP 500 mg/2 mL (250 mg/mL) and 1 Gram/4 mL (250 mg/mL) Vials by Teva: Recall – Glass Particulate Matter
Teva Pharmaceuticals announced a voluntary recall of seven lots of Amikacin Sulfate Injection USP, 500 mg/2mL (250 mg/mL) and 1 gram/4mL (250 mg/mL) vials due to the potential for the presence of glass particulate matter. The administration of a glass particulate, if present in an intravenous drug, may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening if a critical organ is affected. See the press release for a listing of affected lot numbers or look at the chart below.
|Lot #||Exp. Date||Strength||Vial Size||NDC# (Individual Pack)||NDC# (Shelf Pack – carton of 10 vials)|
|2381114||11/2016||1 gm/4 mL (250 mg/mL)||4 mL||0703-9040-01||0703-9040-03|
|2771114||11/2016||1 gm/4 mL (250 mg/mL)||4 mL||0703-9040-01||0703-9040-03|
|4760915||9/2017||1 gm/4 mL (250 mg/mL)||4 mL||0703-9040-01||0703-9040-03|
|7080315||3/2017||500 mg/2 mL (250 mg/mL||2 mL||0703-9032-01||0703-9032-03|
|7400315||3/2017||500 mg/2 mL (250 mg/mL)||2 mL||0703-9032-01||0703-9032-03|
|7410315||3/2017||500 mg/2 mL (250 mg/mL)||2 mL||0703-9032-01||0703-9032-03|
|7980415||4/2017||500 mg/2 mL (250 mg/mL)||2 mL||0703-9032-01||0703-9032-03|
Amikacin Sulfate Injection USP is used in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, and has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease.
Amikacin Sulfate Injection 250 mg/mL, 2 mL & 4 mL vials were distributed nationwide through wholesalers, retailers, and pharmacies.
Teva issued an Urgent Drug Recall Letter to their direct customers. Teva is arranging for impacted product to be returned to Inmar. Anyone with an existing inventory of the recalled lot(s) should stop use and distribution, and quarantine the product immediately. Customers should notify all retail and medical facility accounts. Customers who have further distributed the recalled product should notify any accounts or additional locations which may have received the recalled product and instruct them if they have redistributed the product to notify their accounts, locations, or facilities.
Click here to read the MedWatch safety alert, including a link to the press release.